Core Viewpoint - Hema Medical (03309) experienced a significant stock price increase of over 8%, reaching a price of 2.09 HKD following the announcement of a global licensing and collaboration agreement in the virology field for the drug encequidar with Gilead Sciences, Inc. and Hanmi Pharmaceutical Co., Ltd. [1] Group 1 - Hema Medical's stock opened more than 8% higher and was up 8.85% at the time of reporting, with a trading volume of 380,400 HKD [1] - The agreement involves Hema Medical's subsidiary granting Gilead exclusive global rights to encequidar, which Hema Medical holds outside of South Korea [1] - Hema Medical and Hanmi will provide drug supply, share technical knowledge, and participate as key partners in the project [1] Group 2 - Upon meeting certain conditions and milestones during the agreement period, Hema Medical will receive an upfront payment of 10 million USD [1] - The potential total payments Hema Medical could receive may reach up to approximately 72.5 million USD, along with royalties at a low single-digit percentage of net sales [1]

Core Viewpoint - Hema Medical (03309) experienced a significant stock price increase of over 8%, reaching HKD 2.09, following the announcement of a global licensing and collaboration agreement with Gilead Sciences, Inc. and Hanmi Pharmaceutical Co., Ltd. for the antiviral drug encequidar [1] Group 1: Company Developments - Hema Medical's subsidiary entered into a tripartite global licensing and collaboration agreement regarding the first P-glycoprotein inhibitor in the virology field [1] - The agreement grants Gilead exclusive global rights to encequidar, while Hema Medical and Hanmi will provide drug supply and share technical knowledge [1] - Hema Medical is set to receive an upfront payment of USD 10 million upon meeting certain conditions and milestones during the agreement period, with potential future payments reaching up to approximately USD 72.5 million [1] Group 2: Financial Implications - Hema Medical will also have the right to receive royalties at a low single-digit percentage on net sales of the drug [1]

Company News - China CRRC (01766.HK) signed significant contracts totaling approximately 54.34 billion RMB in the last three months, accounting for about 22% of the company's projected revenue for 2024 under Chinese accounting standards [2] - China Railway Construction (01186.HK) recently secured 14 major projects, each exceeding 1.5 billion RMB, with a total project value of 63.037 billion RMB, representing 5.91% of the company's audited revenue for 2024 [2] - Shenzhen Expressway (00548.HK) reported toll revenues for August from various projects, totaling approximately 134.46 million RMB, 624.58 million RMB, 516.79 million RMB, 714.85 million RMB, and 114 million RMB [2] - Bay Area Development (00737.HK) reported toll revenues for August from several highways, with total revenues of approximately 256 million RMB, 105 million RMB, and 714.85 million RMB, showing a year-on-year decrease of 0.5%, 12%, and an increase of 1% respectively [2] - Hema Medical (03309.HK) entered into a global licensing and collaboration agreement with Gilead and Hanmi regarding encequidar, with an initial payment of 10 million USD and potential future payments up to 72.5 million USD [3] Financial Performance - Times Group Holdings (01023.HK) reported annual revenue of 1.584 billion HKD for the year ending June 30, 2025, a decrease of 1.38%, with a shareholder loss of 178 million HKD, marking a shift from profit to loss [4] - China National Automobile (00026.HK) reported annual revenue of 53.063 million HKD for the year ending June 30, 2025, a decrease of 23.71%, with a narrowed shareholder loss of 185 million HKD, down 29.64% [4] Financing and Share Buybacks - Tencent Holdings (00700.HK) repurchased 837,000 shares at a total cost of 551 million HKD, with prices ranging from 648 to 664 HKD per share [5] - Xiaomi Group-W (01810.HK) repurchased 507,400 shares for a total of 26.996 million HKD, with prices between 53.15 and 53.25 HKD [5] - Hang Seng Bank (00011.HK) repurchased 200,000 shares at a cost of 23.6501 million HKD, with prices ranging from 117.4 to 118.9 HKD [6] - Guofu Hydrogen Energy (02582.HK) completed a placement of 1.9948 million shares at a price of 50.13 HKD per share, raising approximately 98.49 million HKD [7] - Youbao Online (02429.HK) successfully placed 157.5 million shares at a price of 2.45 HKD per share to at least six subscribers [8]

Group 1 - The core announcement involves a tripartite global licensing and collaboration agreement between a subsidiary of Hema Medical, Gilead Sciences, Inc., and Hanmi Pharmaceutical for the first P-glycoprotein inhibitor, encequidar, in the field of virology [1] - Hema Medical and Hanmi will grant Gilead global exclusive rights to encequidar in the virology field, while also providing drug supply, sharing technical knowledge, and participating as key partners in the project [1] - Upon meeting certain conditions and milestones during the agreement period, Hema Medical will receive an upfront payment of $10 million, with potential future payments reaching up to approximately $72.5 million, along with a low single-digit royalty on net sales [1] Group 2 - Hema Medical is primarily engaged in the development of innovative drugs in the oncology field and is currently researching oral formulations of encequidar [2] - The company is preparing to initiate a Phase 3 global clinical study for the treatment of metastatic breast cancer using oral paclitaxel combined with encequidar, aiming to replace intravenous administration of paclitaxel in chemotherapy [2] - The clinical study is planned to commence by the end of 2025 across multiple centers in the United States, Hong Kong, and New Zealand [2]

Group 1 - The core point of the news is that Hema Medical (希华医药) has entered into a global licensing and collaboration agreement with Gilead Sciences and Hanmi Pharmaceutical for the P-glycoprotein inhibitor encequidar, which Hema Medical holds exclusive global rights outside of South Korea [1] - Under the agreement, Hema Medical and Hanmi will grant Gilead exclusive global rights to encequidar in the field of virology, and they will also provide drug supply and share technical knowledge [1] - Hema Medical is set to receive an initial payment of $10 million, with potential future payments reaching up to approximately $72.5 million, along with a low single-digit royalty on net sales [1] Group 2 - Hema Medical is primarily focused on innovative drug development in the oncology field and is currently researching oral formulations of encequidar [2] - The company is preparing to initiate a Phase 3 global clinical study for the treatment of metastatic breast cancer using oral paclitaxel combined with encequidar, which aims to replace intravenous administration of paclitaxel in chemotherapy [2] - The clinical study is planned to commence by the end of 2025 across multiple centers in the United States, Hong Kong, and New Zealand [2]

Group 1 - The core point of the news is that Hema Medical (希华医药) has entered into a global licensing and collaboration agreement with Gilead Sciences, Inc. and Hanmi Pharmaceutical Co., Ltd. for the antiviral drug encequidar, which Hema Medical holds exclusive global rights outside of South Korea [1] - Under the agreement, Hema Medical and Hanmi will grant Gilead exclusive global rights to encequidar in the field of virology, while also providing drug supply and sharing technical knowledge [1] - Hema Medical is set to receive an upfront payment of $10 million, with potential milestone payments reaching up to approximately $72.5 million, along with royalties based on a low single-digit percentage of net sales [1] Group 2 - Hema Medical is primarily focused on innovative drug development in the oncology field and is currently researching oral formulations of paclitaxel combined with encequidar for the treatment of metastatic breast cancer [2] - The company is preparing to initiate a Phase 3 global clinical study for the oral paclitaxel and encequidar regimen for metastatic breast cancer, with plans to conduct the study at multiple centers in the United States, Hong Kong, and New Zealand by the end of 2025 [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 （股份代號：3309） （於開曼群島註冊成立之有限公司） 自願性公告 最新業務進展 希 瑪 醫 療 控 股 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」）董 事 會（「董 事 會」）欣 然 宣 佈，於2025年9月29日，希 華 醫 藥 有 限 公 司（「希華醫藥」）的 一 間 附 屬公司與Gilead Sciences, Inc.（「Gilead」）及 韓 美 藥 品 工 業 株 式 会 社（「韓 美」）就 病 毒 學領域首款P－糖 蛋 白（「P-gp」）抑 制 劑encequidar（希 華 醫 藥 擁 有 該 款 藥 物 在 韓 國 以 外 的 全 球 獨 家 權 利）訂 立 三 方 全 球 授 權 及 合 作 協 議。 根 據 協 議，希 華 醫 藥 及 韓 美 會 將encequidar在病毒學領域的全球獨家權 ...